IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 1019 
Small font sizeDefault font sizeIncrease font size
Navigate Here
  Search
 
  
Resource Links
   Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
   Article in PDF (145 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)

 
In This Article
   References

 Article Access Statistics
    Viewed787    
    Printed15    
    Emailed0    
    PDF Downloaded136    
    Comments [Add]    

Recommend this journal

 


 
 Table of Contents    
LETTER TO THE EDITOR
Year : 2014  |  Volume : 46  |  Issue : 5  |  Page : 564
 

Social pharmacology and diabetes


1 Consultant (Endocrinology and Metabolism), Bharti Hospital, Karnal, Haryana, India
2 Department of Medicine, Government Medical College and Hospital, Chandigarh, India

Date of Web Publication11-Sep-2014

Correspondence Address:
Sanjay Kalra
Consultant (Endocrinology and Metabolism), Bharti Hospital, Karnal, Haryana
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0253-7613.140601

Rights and Permissions



How to cite this article:
Kalra S, Gupta Y. Social pharmacology and diabetes . Indian J Pharmacol 2014;46:564

How to cite this URL:
Kalra S, Gupta Y. Social pharmacology and diabetes . Indian J Pharmacol [serial online] 2014 [cited 2018 Dec 16];46:564. Available from: http://www.ijp-online.com/text.asp?2014/46/5/564/140601


Dear Madam,

We appreciate the comprehensive review article Social Pharmacology: Expanding horizons, which explores the complex concepts which merge together to form this subspecialty of clinical pharmacology. [1]

Social pharmacology is central to pharmacotherapeutics in chronic disease, especially diabetes mellitus. While newer drugs have been developed to address the various pathophysiological defects in diabetes, their availability has not necessarily meant automatic accessibility or acceptance. Neither has this translated into improved glycemic control at a public health level. The reasons for this can be analyzed by the discipline of social pharmacology.

Psychosociocultural factors play an important role in influencing acceptance of, and adherence to chronic therapy, especially injectable drugs. [2] An understanding of these factors is key to encourage persons with diabetes to join health care professionals in a successful 'therapeutic alliance'. Appropriate rational therapy to achieve targets and goals, decided through a process of shared decision making, can be instituted only if the patient is motivated. A person- centered framework, therefore, should be used to describe social pharmacology, instead of the drug- centered model proposed by Maiti and Alloza. [1]

Social pharmacology should also include the study of motivational skills, which are necessary to ensure optimal drug usage. We propose the 3I strategy (Inform- Incubate-Initiate) to encourage use of injectable therapy including insulin and glucagon-like peptide 1 receptor agonists (GLP1RA) in diabetes. This approach is based upon Prochaska's therapy of motivation which proposes that one must move from pre-contemplation to contemplation (that is, incubation), before action (initiation) can take place. [3] For example: Initiation of insulin in a diabetic patient, who is uncontrolled on diabetes. A patient may not readily accept the advice for insulin initiation instantly, if he is not acutely ill or severely symptomatic. Such patients can be informed regarding need for insulin for glycaemic control, postponed till the next visit. This moves them from pre-contemplation (No thought for insulin therapy) phase to contemplation phase (thoughts for insulin therapy), which we call the incubation period. Such patients while trying their maximum effort for glycaemic control, also gets ready for insulin, if their glucose control is not good at the next visit. The initiation of insulin then becomes easier, and the relapse rates (moving back to oral anti-diabetic agents) decreases.

Social pharmacology must involve family and community as well, as these are important stakeholders in diabetes care. [4] The need for well-made educational materials for persons with diabetes and their family members is also covered in this field.

Social pharmacology, already a well-developed field, [1] can be further strengthened by involving diabetes care professionals, people with diabetes, and their family members. The Indian Journal of Pharmacology should be appreciated for providing a platform to achieve better utilization of available drugs using validated socio-pharmacological approaches.

 
  References Top

1.Maiti R, Alloza JL. Social Pharmacology: Expanding horizons. Indian J Pharmacol 2014;46:246-50.  Back to cited text no. 1
[PUBMED]  Medknow Journal  
2.Kalra S, Baruah MP, Sahay R. Person centered care in the Second Diabetes Attitudes, Wishes and Needs (DAWN2) study: Inspiration from India. Indian J Endocrinol Metab 2014;18:4-6.  Back to cited text no. 2
    
3.Prochaska JO, Velicer WF. The transtheoretical model of health behavior change. Am J Health Promot 1997;12:38-48.  Back to cited text no. 3
    
4.Kalra S, John M, Baruah MP. The Indian family fights diabetes: Results from the second Diabetes Attitudes, Wishes and Needs (DAWN2) study. J Soc Health Diabetes 2014;2:3-5.  Back to cited text no. 4
  Medknow Journal  




 

Top
Print this article  Email this article
 

    

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer
Online since 20th July '04
Published by Wolters Kluwer - Medknow